License-driven growth led to a 17.3% revenue increase and positive EBITDA in 2024, with improved margins and cash flow. The Zimmer Biomet agreement termination prompted a review of financial targets, while new licensing and R&D initiatives support future growth.
Original document:
This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.